Table 3.
MYDGF in kidney diseases
| Disease | Model | Effect | Pathway | Reference |
|---|---|---|---|---|
| Renal IR injury | C57BL/6 mice, HK-2 and Human Kidney Cell | Improve renal function, reduce oxidative stress, inflammation, and apoptosis | The phosphorylation Akt | (Wang et al. 2023a, b) |
| Focal segmental glomerulosclerosis | Podocyte-specific MYDGF knockout mice | Protected podocytes against mitotic catastrophe | RUNX2/P27/cyclinA/CDK2 | (Zhan et al. 2022) |
| Diabetic kidney disease | Podocyte-specific MYDGF knockout mice, MYDGF-/- mice | Protected podocytes against mitotic catastrophe, preserve nephrin expression and inhibit podocyte apoptosis | RUNX2/P27/cyclinA/CDK2, Akt/BAD | (Zhan et al. 2022; He et al. 2020) |
| CKD | C57BL/6J mice, Wistar rats | Alleviate capillary rarefaction, hypoxia, renal fibrosis, and tubular atrophy | Remain unknown | (Du et al. 2022) |